Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tema GLP-1, Obesity & Cardiometabolic ETF (NQ: HRTS ) 34.84 +0.54 (+1.57%) Official Closing Price Updated: 4:15 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 47,120 Open 34.67 Bid (Size) 34.80 (2) Ask (Size) 35.00 (8) Prev. Close 34.30 Today's Range 34.37 - 34.94 52wk Range 26.26 - 36.03 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' July 18, 2024 Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. Via Benzinga EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO July 07, 2024 The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. Via Benzinga Topics ETFs Performance YTD +13.65% +13.65% 1 Month +4.36% +4.36% 3 Month +11.95% +11.95% 6 Month +10.88% +10.88% 1 Year +30.85% +30.85% More News Read More What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients July 05, 2024 Via Investor's Business Daily Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply May 29, 2024 Via Benzinga Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test April 17, 2024 Via Investor's Business Daily Healthcare ETFs For The Weight-Loss Drug Boom And Beyond April 08, 2024 Via Talk Markets Topics Artificial Intelligence ETFs Exposures Artificial Intelligence Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. February 23, 2024 Via Investor's Business Daily Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing January 29, 2024 Via Benzinga Topics ETFs Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market December 04, 2023 Via Benzinga EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads December 01, 2023 Via Benzinga Topics ETFs Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
